HF
VRTX icon

HRT Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

HRT Financial’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,500
Closed -$3.52M – 3803
2022
Q1 		$3.52M Buy
+13,500
New +$3.2M 0.03% 393

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HRT Financial's VRTX Position: Q2 2026 in Review

HRT Financial increased its Vertex Pharmaceuticals (VRTX) stake by 51% in Q2 2026, buying an estimated $6.09M and bringing the position to 40,533 shares worth $20.1M. The position accounts for 0.04% of the portfolio, ranked #478.

HRT Financial first reported a position in VRTX in Q3 2015 and has held it in 16 quarters since. The position peaked at $57.9M in Q2 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • HRT Financial held 40,533 shares of Vertex Pharmaceuticals worth $20.1M as of Q2 2026.
  • HRT Financial bought 13,743 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.09M.
  • Vertex Pharmaceuticals made up 0.04% of HRT Financial's portfolio in Q2 2026, its #478 holding.
  • HRT Financial first reported a position in Vertex Pharmaceuticals in Q3 2015 and has held it in 16 quarters since.
  • HRT Financial's Vertex Pharmaceuticals position peaked at $57.9M in Q2 2024.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.